Earnings Bonanza: Exclusive Stock Alert Inside!

This is a must read. If you cannot see this email properly, please click [here]( --------------------------------------------------------------- Sponsor Message [Game-Changing Cancer Tech Nears FDA Completion]( [Explore Investment Opportunities in This Market Disruptor]( --------------------------------------------------------------- March 1, 2024 (Earnings Report) From the desk of the Editor Dear Reader, We just identified several stocks that are expected to release earnings very soon. If you are interested in any of these companies, we encourage you to do your own research and due diligence before pursuing any investments. Keep in mind, the actual earnings date and time may change, so if you’re interested in any of these companies you will need to pay close attention to their announcements. --------------------------------------------------------------- Sponsor Message [Revolutionary Device Redefines Cancer Detection]( the breakthrough device that could transform the lives of the estimated 68 million Americans affected by skin cancer. Achieving unprecedented accuracy, this device identifies cancer's molecular signature in just 1.5 seconds. This innovation marks a rapid advance in the battle against cancer. See how investors are unlocking 10% in bonus shares for a limited time. [Learn More Now - Before Anticipated FDA Approval in 2024]( --------------------------------------------------------------- [Instil Bio, Inc.]( Symbol: [TIL]( Recent Price: $11.92 Average Analyst Price Target: $36.00 (202.01%) Market Cap: $77.53M Last Year's EPS: $-2.2 Consensus EPS Forecast: $-2.8 Expected Earnings Date: Mar 04, 2024 Recent Analyst Action: Mitchell Kapoor, analyst at H.C. Wainwright, reiterates coverage on [Instil Bio, Inc. (TIL)]( in the Healthcare sector with a Buy rating and a price target of $18 (1 month ago). [TipRanks.com]( also reports that [Instil Bio, Inc.]( currently has 2 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $36.00 . The target pricing ranges from a high forecast of $54 down to a low forecast of $18. [Instil Bio, Inc. (TIL)](’s last closing price was $11.92 which would put the average price target at 202.01% upside. Here are 3rd party ratings for [TIL](: - TipRanks.com: Buy - TradingView.com: Buy - Yahoo! Finance: Neutral Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Buy, Top 31% (79 out of 251) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [#1 Stock for Energy Crisis (Buy Now for Just $8)]( the world suffers an oil shock… And gas prices rip higher… One tiny company could have the answer to the global energy crisis. It’s using AI to crack open the largest untapped energy source on the planet… 5X larger than the biggest oil field on Earth. [Act fast, this $8 stock could be moments away from appreciating considerably.]( --------------------------------------------------------------- [Ondas Holdings Inc.]( Symbol: [ONDS]( Recent Price: $1.27 Average Analyst Price Target: $2.50 (96.85%) Market Cap: $83.26M Last Year's EPS: $-0.18 Consensus EPS Forecast: $-0.16 Expected Earnings Date: Mar 04, 2024 Recent Analyst Action: Glenn G, analyst at Ladenburg Thalmann & Co., reiterates coverage on [Ondas Holdings Inc. (ONDS)]( in the Technology sector with a Buy rating and a price target of $3.5 (2 months ago). [TipRanks.com]( also reports that [Ondas Holdings Inc.]( currently has 3 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $2.50 . The target pricing ranges from a high forecast of $3.5 down to a low forecast of $2. [Ondas Holdings Inc. (ONDS)](’s last closing price was $1.27 which would put the average price target at 96.85% upside. Here are 3rd party ratings for [ONDS](: - TipRanks.com: Buy - TradingView.com: Sell - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: buy - Zacks.com: Hold, Bottom 8% (231 out of 251) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Digital Dollar: Convenience or Control?]( the truth behind the digital dollar. Is it a step towards financial innovation or a leap into surveillance and control? See how you can protect yourself and your money with our free guide. [Protect Your Money ASAP]( --------------------------------------------------------------- [Cara Therapeutics, Inc.]( Symbol: [CARA]( Recent Price: $0.85 Average Analyst Price Target: $5.90 (594.12%) Market Cap: $46.32M Last Year's EPS: $-0.58 Consensus EPS Forecast: $-0.53 Expected Earnings Date: Mar 04, 2024 Recent Analyst Action: Sumant Kulkarni, analyst at Canaccord Genuity, reiterates coverage on [Cara Therapeutics, Inc. (CARA)]( in the Healthcare sector with a Buy rating and a price target of $11 (1 month ago). [TipRanks.com]( also reports that [Cara Therapeutics, Inc.]( currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $5.90 . The target pricing ranges from a high forecast of $5 down to a low forecast of $1. [Cara Therapeutics, Inc. (CARA)](’s last closing price was $0.85 which would put the average price target at 594.12% upside. Here are 3rd party ratings for [CARA](: - TipRanks.com: Buy - TradingView.com: Neutral - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: sell - Zacks.com: Hold, Top 31% (79 out of 251) [Click for chart >>]( -------------------------------------------------------------------------- [Ekso Bionics Holdings, Inc.]( Symbol: [EKSO]( Recent Price: $1.90 Average Analyst Price Target: $10.00 (426.32%) Market Cap: $33.85M Last Year's EPS: $-0.31 Consensus EPS Forecast: $-0.31 Expected Earnings Date: Mar 04, 2024 Recent Analyst Action: Swayampakula Ramakanth, analyst at H.C. Wainwright, reiterates coverage on [Ekso Bionics Holdings, Inc. (EKSO)]( in the Healthcare sector with a Buy rating and a price target of $10 (1 month ago). [TipRanks.com]( also reports that [Ekso Bionics Holdings, Inc.]( currently has 1 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $10.00 . The target pricing ranges from a high forecast of $10 down to a low forecast of $10. [Ekso Bionics Holdings, Inc. (EKSO)](’s last closing price was $1.90 which would put the average price target at 426.32% upside. Here are 3rd party ratings for [EKSO](: - TipRanks.com: Buy - TradingView.com: Sell - Yahoo! Finance: Neutral Short-Term Outlook - Barchart.com: buy - Zacks.com: Buy, Top 33% (84 out of 251) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [My Gift to You]( I have arranged for you to receive [a complimentary 3-month subscription]( to Bernie Schaeffer’s Option Advisor online newsletter. [CLICK HERE]( for 3 Months FREE of Bernie Schaeffer’s Option Advisor ($395 Retail Value - [FREE!]() --------------------------------------------------------------- [AnaptysBio, Inc.]( Symbol: [ANAB]( Recent Price: $25.53 Average Analyst Price Target: $49.80 (95.06%) Market Cap: $678.46M Last Year's EPS: $-1.5 Consensus EPS Forecast: $-1.72 Expected Earnings Date: Mar 04, 2024 Recent Analyst Action: Julian Harrison, analyst at BTIG, reiterates coverage on [AnaptysBio, Inc. (ANAB)]( in the Healthcare sector with a Buy rating and a price target of $55 (4 days ago). [TipRanks.com]( also reports that [AnaptysBio, Inc.]( currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $49.80 . The target pricing ranges from a high forecast of $80 down to a low forecast of $20. [AnaptysBio, Inc. (ANAB)](’s last closing price was $25.53 which would put the average price target at 95.06% upside. Here are 3rd party ratings for [ANAB](: - TipRanks.com: Buy - TradingView.com: Buy - Yahoo! Finance: Neutral Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Hold, Top 31% (79 out of 251) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Detecting Cancer in 1.5 Seconds: Early Investment Opportunity]( Stanford engineer's lofty goal of revolutionizing cancer diagnostics is expected to come to fruition with FDA review in its final stages. With a history of taking companies public, including a $2 billion market cap NASDAQ company, this may be his biggest venture yet! With the ability to detect cancer's "molecular fingerprint" in just 1.5 seconds, it also offers far superior accuracy to current detection methods! [Learn more about how this could transform the multi-billion dollar diagnostic market.]( --------------------------------------------------------------- And there you have it--- Stocks expected to release earnings soon... Sincerely, The Editor, MarketMoverAlerts.com Disclaimer This email/newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this email/newsletter is not provided to any individual with a view toward their individual circumstances. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this email/newsletter as the basis for any investment decision. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our email/newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.[If you are not a human, click here.](By opening and/or clicking on any link contained within this email, you are reconfirming your opt-in status. You can unsubsubscribe at any time by clicking on the link in the footer. MarketMoverAlerts.com part of Sandpiper Marketing Group | 1519 Mecklenburg Hwy | Unit 4 | Mt. Mourne | | NC | 28123 | United States | 877-411-9808 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software